FindTrial
Sign In

A multicenter study on the effects of GLP-1 receptor agonist or high-fiber diet intervention on metabolic and endocrine status in overweight /obese people

Effects of GLP-1 receptor agonist or high-fiber diet intervention on metabolic and endocrine status in overweight /obese people

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200066014
Enrollment
Unknown
Registered
2022-11-22
Start date
2022-12-01
Completion date
Unknown
Last updated
2026-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight or Obesity

Interventions

High-fiber diet intervention group:High-fiber diet
GLP-1 receptor agonist intervention group:Semaglutide is administered subcutaneously: 0.25mg once weekly for the first two weeks, 0.5mg once weekly for the third and fourth weeks, and 1mg once weekly

Sponsors

Shanghai General Hospital, Shanghai Jiao Tong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. BMI >= 24 kg/m2; 2. Aged 18-60 years; 3. No diabetes; 4. Not currently participating in other research projects; 5. Implementing contraception during the study period.

Exclusion criteria

Exclusion criteria: 1. Pregnancy or lactation. 2. Weight loss through medication or surgery within 3 months pre-enrollment. 3. Use of antibiotics within two weeks. 4. Severe liver, kidney and other chronic diseases. 5. Diagnosed with diabetes. 6. Allergy to semaglutide. 7. Have recently taken liver-protective drugs or lipid-lowering drugs. 8. Have chronic diarrhea, irritable bowel syndrome (IBS), or inflammatory bowel disease (IBD).

Design outcomes

Primary

MeasureTime frame
Percentage change of weight;—

Secondary

MeasureTime frame
Percentage change of Body Mass Index;Percentage change of waist circumference;Percentage change of hip circumference;Percentage change of waist-to-hip ratio;Percentage change of blood pressures;Percentage change of body fat;Percentage change of body lean mass;Percentage changes of blood glucoses;Percentage change of HbA1c;Percentage change of insulin;Percentage change of c-peptide;Percentage change of insulin resistance level (HOMA2-IR);Percentage changes of Total Cholesterol;Percentage changes of Triglycerides;Percentage changes of Low-Density Lipoprotein Cholesterol;Percentage changes of High-Density Lipoprotein Cholesterol;Percentage changes of Alanine Aminotransferase in serum;Percentage changes of Aspartate Aminotransferase in serum;Percentage changes of Serum Creatinine;Percentage changes of Serum Uric Acid;Percentage changes of anxiety and depression scores;—

Countries

China

Contacts

Public ContactXiaoying Ding, Yi Lin

Department of Endocrinology, Shanghai General Hospital

xiaoyingding@126.com+86 189 1722 7753

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026